Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial.
Am J Drug Alcohol Abuse
; 46(1): 44-48, 2020.
Article
en En
| MEDLINE
| ID: mdl-31339797
ABSTRACT
Background:
Currently, there are no established pharmacotherapies for cannabis use disorders (CUDs). As a long-acting alpha-2-adrenergic receptor agonist, guanfacine extended-release (G-XR) could be useful in the treatment of CUDs by mitigating withdrawal and improving behavioral control.Objectives:
To evaluate the feasibility and tolerability of G-XR as a treatment for CUDs.Methods:
In an eight-week open-label outpatient pilot trial, we evaluated the safety and tolerability of G-XR in 22 cannabis dependent individuals. Using 2 different titration schedules, G-XR was gradually titrated to a dose of 4 mg or the highest dose tolerated. All participants received standard medication management.Results:
Retention at week eight was 41%. Average daily amount of cannabis use (in grams F1,86 = 8.74, p = .004; in dollars F1,86 = 16.67, p < .0001) and cannabis using days (F1,86 = 7.67, p = .007) significantly reduced over the course of study participation. There were no significant differences between the titration schedules on emergence of side effects (Fisher exact test, p = .378) or retention (Log-Rank Test X21 = 0.021, p = .886). A total of 3 participants achieved 3 weeks or greater of total abstinence.Conclusions:
G-XR is a feasible treatment for CUDs, and should be evaluated further in an efficacy trial.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Abuso de Marihuana
/
Guanfacina
/
Agonistas de Receptores Adrenérgicos alfa 2
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Am J Drug Alcohol Abuse
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos